Form S-1MEF Beta Bionics, Inc.
As filed with the Securities and Exchange Commission on January 29, 2025.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Beta Bionics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 3841 | 47-5386878 | ||
| (State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification No.) |
Beta Bionics, Inc.
11 Hughes, Suite 100
Irvine, CA
(619) 937-2754
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Sean Saint
President and Chief Executive Officer
Beta Bionics, Inc.
11 Hughes
Irvine, California 92618
(949) 427-7785
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
| Carlos Ramirez Mark Weeks Charles S. Kim Cooley LLP 10265 Science Center Drive San Diego, California 92121 (858) 550-6000 |
Nathan Ajiashvili Ross McAloon Matthew T. Bush Latham & Watkins LLP 1271 Avenue of the Americas New York, New York 10020 (212) 906-1200 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (333-284147)
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the Securities Act) by Beta Bionics, Inc. (the Registrant), for the sole purpose of increasing the aggregate number of shares of common stock offered and registered by the Earlier Registration Statement (as defined below) by 2,300,000 shares, 300,000 of which are subject to purchase upon exercise of the underwriters option to purchase additional shares of the Registrants common stock. The contents of the Registration Statement on Form S-1, as amended (File No. 333-284147), including all exhibits thereto (the Earlier Registration Statement), filed by the Registrant with the Securities and Exchange Commission (the Commission) pursuant to the Securities Act, which was declared effective by the Commission on January 29, 2025, are incorporated by reference into this Registration Statement. The additional shares of common stock that are being registered for issuance and sale pursuant to this Registration Statement are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 of the Earlier Registration Statement.
The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.
EXHIBIT INDEX
| Exhibit No. |
Exhibit Index | |
| 5.1 | Opinion of Cooley LLP. | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | |
| 23.4 | Consent of Cooley LLP (included in Exhibit 5.1). | |
| 24.1* | Power of Attorney. | |
| 107 | Filing Fee Table. | |
| * | Previously filed on the signature page to the Registrants Registration Statement on Form S-1 (File No. 333-284147), originally filed with the Securities and Exchange Commission on January 6, 2025 and incorporated by reference herein. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Irvine, California on January 29, 2025.
| BETA BIONICS, INC. | ||
| By: | /s/ Sean Saint | |
| Sean Saint | ||
| President and Chief Executive Officer | ||
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities held on the dates indicated.
| Signature |
Title |
Date | ||
| /s/ Sean Saint Sean Saint |
President, Chief Executive Officer and Director (Principal Executive Officer) |
January 29, 2025 | ||
| /s/ Stephen Feider Stephen Feider |
Chief Financial Officer (Principal Financial and Accounting Officer) |
January 29, 2025 | ||
| * Adam Lezack |
Chairperson of the Board of Directors | January 29, 2025 | ||
| * Sean Carney |
Member of the Board of Directors | January 29, 2025 | ||
| * Dan Dearen |
Member of the Board of Directors | January 29, 2025 | ||
| * Christy Jones |
Member the Board of Directors | January 29, 2025 | ||
| * Maria Palasis, Ph.D. |
Member of the Board of Directors | January 29, 2025 | ||
| *By: | /s/ Sean Saint | |
| Sean Saint | ||
| Attorney-in-Fact |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Beta Bionics Investors Who Lost Money: Contact Block & Leviton LLP About the Pending Securities Litigation
- Keysight to Demonstrate End-to-End Solutions for Scaling AI Infrastructure at ECOC 2026
- Beta Bionics closes $172.5M public stock offering on Nasdaq
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share